JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CWEN.A
2826
DELISTED
Clearway Energy Class A
CWEN.A
| $3.5M | ﹤0.01% |
185,501
+3,984
| +2% | +$74.9K |
2015 Q2
10 quarters
|
|
|
COUP
2827
DELISTED
Coupa Software Incorporated
COUP
| $3.49M | ﹤0.01% |
111,913
-16,764
| -13% | -$569K |
2016 Q4
4 quarters
|
|
|
XIFR
2828
XPLR Infrastructure LP
XIFR
$980M
| $3.48M | ﹤0.01% |
80,816
-946
| -1% | -$38K |
2014 Q4
12 quarters
|
|
2829
PRA Group
PRAA
$710M
| $3.48M | ﹤0.01% |
104,889
+52,175
| +99% | +$1.66M |
2013 Q2
18 quarters
|
|
|
MIC
2830
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $3.48M | ﹤0.01% |
54,249
-37,322
| -41% | -$2.53M |
2013 Q2
18 quarters
|
|
2831
Installed Building Products
IBP
$5.13B
| $3.48M | ﹤0.01% |
45,825
+14,440
| +46% | +$1M |
2017 Q1
3 quarters
|
|
|
XNET
2832
PUT
Xunlei
XNET
$300M
| $3.48M | ﹤0.01% |
+226,000
| New | +$2.59M |
2017 Q4
0 quarters
|
|
2833
PDS Biotechnology
PDSB
$54.2M
| $3.48M | ﹤0.01% |
18,548
-406
| -2% | -$81.7K |
2015 Q4
8 quarters
|
|
2834
iShares MSCI Australia ETF
EWA
$1.21B
| $3.47M | ﹤0.01% |
149,899
-438,695
| -75% | -$10M |
2013 Q2
18 quarters
|
|
2835
Albany International
AIN
$1.73B
| $3.47M | ﹤0.01% |
56,419
+49,105
| +671% | +$2.96M |
2013 Q2
18 quarters
|
|
2836
Gentherm
THRM
$962M
| $3.46M | ﹤0.01% |
109,118
+86,325
| +379% | +$2.99M |
2014 Q3
13 quarters
|
|
|
ISCA
2837
DELISTED
International Speedway Corp
ISCA
| $3.46M | ﹤0.01% |
86,842
+6,797
| +8% | +$270K |
2015 Q4
8 quarters
|
|
2838
ANI Pharmaceuticals
ANIP
$1.66B
| $3.44M | ﹤0.01% |
53,425
-51,404
| -49% | -$3.2M |
2016 Q1
7 quarters
|
|
2839
GSK
GSK
$94.2B
| $3.44M | ﹤0.01% |
77,562
-44,882
| -37% | -$2.07M |
2013 Q2
18 quarters
|
|
2840
Fox Factory Holding Corp
FOXF
$784M
| $3.43M | ﹤0.01% |
88,370
+6,243
| +8% | +$253K |
2017 Q2
2 quarters
|
|
|
TRK
2841
DELISTED
Speedway Motorsports, Inc.
TRK
| $3.43M | ﹤0.01% |
181,998
-1,473
| -0.8% | -$30K |
2013 Q2
18 quarters
|
|
|
SASR
2842
DELISTED
Sandy Spring Bancorp Inc
SASR
| $3.43M | ﹤0.01% |
87,862
+33,753
| +62% | +$1.36M |
2015 Q4
8 quarters
|
|
2843
Rhythm Pharmaceuticals
RYTM
$6.39B
| $3.43M | ﹤0.01% |
+117,977
| New | +$3.12M |
2017 Q4
0 quarters
|
|
2844
Viridian Therapeutics
VRDN
$2.2B
| $3.43M | ﹤0.01% |
21,903
+613
| +3% | +$78.1K |
2017 Q3
1 quarter
|
|
|
CXP
2845
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
| $3.42M | ﹤0.01% |
149,073
+92,637
| +164% | +$2.06M |
2014 Q2
14 quarters
|
|
|
HRG
2846
DELISTED
HRG Group, Inc.
HRG
| $3.42M | ﹤0.01% |
201,661
+153,504
| +319% | +$2.48M |
2015 Q2
10 quarters
|
|
2847
CALL
F5
FFIV
$25.7B
| $3.41M | ﹤0.01% |
26,000
| – | – |
2017 Q3
1 quarter
|
|
2848
Medpace
MEDP
$16.7B
| $3.41M | ﹤0.01% |
93,939
+93,739
| +46,870% | +$3.29M |
2017 Q3
1 quarter
|
|
2849
PUT
Nektar Therapeutics
NKTR
$1.49B
| $3.4M | ﹤0.01% |
+3,800
| New | +$2.25M |
2017 Q4
0 quarters
|
|
2850
Photronics
PLAB
$1.86B
| $3.4M | ﹤0.01% |
398,701
+123,330
| +45% | +$1.13M |
2016 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.